All posts tagged fred hirsch

  • TLymphocyte

    Lancet Oncology: Survival benefit with “fully human” EGFR antibody necitumumab in squamous non-small cell lung cancer

    With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

DNA
C3Fall2013_Final-7.2
Fred R. Hirsch
Pills
Subway.Map1
Flickr: Sepher Ehsani
Flickr: Sara | B.
Fred R. Hirsch, MD, PhD, investigator at the University of Colorado Cancer Center and